Showing results (41-50 of 52) with videos related to
Sort By:
Pageof 6
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 3, 2011
(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinibMatthias R Benz, Ken Herrmann, Franziska Walter, et al.Proteomics. Clinical Applications|December 8, 2010
Consistency of a two clinical site sample collection: a proteomics studyCedric Wiesner, Charles Hannum, Karen Reckamp, et al.Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 7, 2004
Multifaceted roles of cyclooxygenase-2 in lung cancerKaren Riedl, Kostyantyn Krysan, Mehis Põld, et al.Oncotargets and Therapy|September 23, 2021
Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient SelectionAlexis LeVee, Ching Ying Lin, Edwin Posadas, et al.Lancet (London, England)|July 8, 2008
An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trialChristopher Wood, Pramod Srivastava, Ronald Bukowski, et al.The Lancet. Oncology|April 3, 2023
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 studyToni K Choueiri, David F McDermott, Jaime Merchan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2004
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancerEric K Rowinsky, Garry H Schwartz, Jared A Gollob, et al.Cancer Research|September 17, 2011
Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480Hong Xin, Andreas Herrmann, Karen Reckamp, et al.The Lancet. Oncology|January 5, 2025
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 studyToni K Choueiri, Jaime R Merchan, Robert Figlin, et al.The New England Journal of Medicine|June 1, 2007
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinomaGary Hudes, Michael Carducci, Piotr Tomczak, et al.Pageof 6